Bayer Animal Health Announces the Launch of AdvantageÃ‚® II and K9 AdvantixÃ‚® II
SHAWNEE, Kan., Jan. 31, 2011 /PRNewswire/ -- Bayer Animal Health announced this month at the North American Veterinary Conference, the availability of its new products: Advantage® II for cats and dogs, and K9 Advantix® II for dogs. These products combine the adulticidal properties of the original formulations of Advantage® Topical Solution and K9 Advantix®, with the insect growth regulator (IGR) pyriproxyfen, which inhibits the development of flea eggs and kills flea larvae. As a result, Advantage® II and K9 Advantix® II kill all flea life stages and prevent fleas on a treated dog from infesting the home. These products will be available in March 2011.
Pyriproxyfen, the added compound in Advantage® II and K9 Advantix® II, interferes with the hormone signaling of growing insects so that fleas in immature stages are unable to mature. The hormone pathway that pyriproxyfen targets is specific to insects and does not affect mammals.
"Adding pyriproxyfen to the original formulations of Advantage® Topical Solution and K9 Advantix® gives an added layer of protection to our customers' pets and their pets' surroundings. It interrupts the flea life cycle at multiple stages, and prevents reinfestation," said Peter Ryan, Vice President & Head, Companion Animal Business Unit, Bayer Animal Health.
Advantage® II and K9 Advantix® II have adulticidal, larvicidal and ovicidal properties, killing adult fleas and preventing the emergence of new ones. Disrupting the flea life cycle through different active ingredients and modes of action is often referred to as integrated flea control (IFC). Imidacloprid quickly paralyzes a flea's mouthparts and kills fleas through contact, so fleas don't have to bite your pet to die. By protecting pets from fleas, imidacloprid has been shown to reduce the incidence of certain conditions including flea al